Truist Securities Maintains Hold on Sage Therapeutics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee maintains a Hold rating on Sage Therapeutics (NASDAQ:SAGE) and lowers the price target from $22 to $18.
April 26, 2024 | 3:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities maintains a Hold rating on Sage Therapeutics and lowers the price target from $22 to $18.
The reduction in the price target by Truist Securities suggests a bearish outlook on the stock's short-term price movement, potentially leading to a negative impact on investor sentiment and the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100